Oxford-based Ultromics, which uses AI to detect heart conditions early through echocardiogram analysis, has raised $55 million in a Series C round to scale its FDA-cleared EchoGo® platform across the US healthcare system.
- Founded in 2017 by Ross Upton out of the University of Oxford, Ultromics develops FDA-cleared, AI-powered software that analyzes standard echocardiograms to detect early signs of heart disease.
- The firm's flagship platform, EchoGo®, is trained on one of the largest real-world echocardiogram datasets globally and has been validated in over 25 peer-reviewed studies.
- The software integrates seamlessly into existing clinical workflows without requiring new hardware, offering real-time probability scores to help clinicians identify high-risk patients earlier.
- Ultromics addresses a significant diagnostic gap, where up to 64% of HFpEF cases go undiagnosed by extracting hidden disease signals from routine cardiac scans.
- Its technology is reimbursable under Medicare and already in use at several US health systems, including Mayo Clinic, UChicago Medicine, and Northwestern.
Details of the deal
- Ultromics’ recent $55 million Series C funding round was co-led by Legal & General (L&G), Allegis Capital, and Lightrock.
“What’s exciting about Ultromics is how they’re closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it’s a diagnostic win that will help save lives," explains Victor Westerlind, Managing Director at Allegis Capital.
- Other investors include Oxford Science Enterprises, Google Ventures, Blue Venture Fund, Oxford University, UChicago Medicine’s venture arm (UCM Ventures), and UPMC Enterprises.
- Ultromics plans to use the $55 million Series C funding to accelerate the nationwide expansion of its AI-powered heart failure diagnostic platform across US hospitals and echo labs. The company aims to integrate its technology into routine cardiac care, enabling earlier and more accurate detection of complex heart conditions.
- Additionally, Ultromics will invest in advancing its product pipeline, exploring new distribution channels, and strengthening collaborations with healthcare systems and clinical leaders to enhance patient outcomes and address the growing heart failure crisis.
“We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis," said Ross Upton, CEO and founder of Ultromics.
